Serum Aldosterone Level in Patients with Diabetic Nephropathy in Relation to Vascular Calcification

Balqies H.Saleh *,1, Shatha H.Ali * and Khalid I. Allehibi**

* Department of Clinical Laboratory Science, College of Pharmacy, University of Baghdad, Baghdad, Iraq.
** Consultant Endocrinologist, Specialized Center for Endocrinology and Diabetes, , Baghdad, Iraq.

Abstract

Diabetic Nephropathy (DN) is a complex disease manifested by persistence microalbuminuria occurring due to the interaction between hemodynamic and metabolic pathway that activates the local renin-angiotensin-aldosterone system resulting in a decline in renal functions. This study aimed to quantify the associations between serum aldosterone concentration and fetuin-A as a marker of calcification in type 2 diabetic patients with and without microalbuminuria from one side, and study the possible relationship between aldosterone and fetuin-A with glycemic indices, serum electrolyte, renal function and microalbuminuria and body mass index from the other side.

A case-control study involved eighty-six adult subjects classified into three groups after testing urine microalbumin including thirty-two diabetics type 2 patients with positive microalbuminuria and twenty-eight diabetics type 2 patients with negative microalbuminuria and 26 healthy subjects during their visit to AL kindy specialized Center for Endocrinology and Diabetes / Baghdad. Those patients were compared to control group of 26 apparently healthy subjects, fasting blood samples was obtained from each of them in one occasion only to measure: fasting serum glucose, electrolyte, aldosterone, fetuin-A, urea, and creatinine. In addition to glycoheamoglobin, glomerular filtration rate and body mass index.

Despite the presence of microalbuminuria in thirty-two of the studied diabetics, there was no positive correlation between aldosterone and fetuin-A, besides that no significant variations in serum aldosterone, glomerular filtration rate (GFR) values, while both groups showed a significant increase in fasting serum glucose and glycoheamoglobin, significant decrease in serum sodium and chloride in comparison with the control group, significant increase was detected in serum fetuin-A mean values in microalbuminuric diabetics. Whereas, negative microalbuminuric diabetics measures expressed a positive correlation between both serum sodium and chloride levels and fetuin-A.

The conclusion of this study diabetic patient are prone to vascular calcification (VC) might be due to increase in aldosterone level or due to diabetic itself from this study we can conclude microalbuminuria can occur without a decline in renal function or a change in estimated GFR, no definite correlation occur between aldosterone and fetuin-A, fetuin-A mean values are higher in diabetic patient with microalbuminuria compared to diabetic patients without microalbuminuria and control group and this referred to uncontrolled diabetes, aldosterone show a correlation with weight and body mass index while fetuin-A does not show such correlation.

In general, electrolyte disturbances (hypernatremia) is more obvious in this study, and its occurrence is due to diabetic (osmotic diuresis) or drugs, while sodium retention which is a sign of aldosterone increment does not occur. Hypochloremia that occur in this study is due to chloride and it is in parallel with sodium level.

Keywords: Aldosterone, Fetuin A, Vascular Calcification, Type 2 Diabetes Mellitus, Glomerular Filtration Rate, Diabetic Nephropathy (DN).

مستويات الالدوستيرون في مصل الدم في مرضى السكري الذين يعانون من اعتلال الكلى السكري وعلاقتة بتكلس الأوعية الدموية.

بلقيس هشام صالح*1، شذى حسين علي* و خالد ابراهيم اللهبي**

* فرع العلوم المختبرية السريرية،كلية الصيدلة،جامعة بغداد،بغداد،العراق.
** استشاري بمرضاز الغدد الصماء والسكري،المركز التخصصي لأمراض الغدد الصماء والسكري،بغداد،العراق.

الخلاصة

إعتلال الكلى السكري هو مرض يعمرت بسب التفاعل بين مسار الدورة الدموية والتمثيل الغذائي الذي ينشط نظام الريبين Analoumelins الألدوستيرون المحلي مما يؤدي إلى انخفاض في وظائف الكلى.

1Corresponding author E-mail: b_h_s86@yahoo.com
Received: 23/8/2018
Accepted: 11/11/2018
Alcohol and calcification

**Introduction**

Diabetic nephropathy (DN) is one of the microvascular complications that develops in about 30% of patients with type 1 diabetes mellitus and about 40% in those with Type 2 diabetes mellitus (T2DM) (1). It is characterized by albuminuria, irreversible decrease in glomerular filtration rate (GFR) and arterial hypertension (2).

Microalbuminuria is an earlier sign of general vascular dysfunction and nowadays is considered a predictor of worse outcomes for both kidney and heart (3). Hence, patients with T2DM should be screened for microalbuminuria from the date of diagnosis (4). With diagnostic reference standard of 30 to 300 mg of albumin in a 24-hour urine sample (5). Persons with type 1 or 2 diabetes and microalbuminuria should continue to be tested for albuminuria annually to observe disease progression and response to therapy (4).

Essential causes in the pathogenesis of diabetic nephropathy are metabolic and hemodynamic pathways (6). Hemodynamic pathway had been reported to include activation of local Renin Angiotensin Aldosterone System (RAAS) in proximal tubular epithelial cells, mesangial cells, and podocyte (7). With consequences of reactive oxygen species (ROS) generation, inflammation, over expression of transforming growth factor-β (TGF-β), and deregulation of different vascular growth factors such as the vascular endothelial growth factor-A (VEGF-A) (8). Activating local (RAAS) results in increased angiotensin II (Ang II), in addition to action Adrenocorticotropic hormone (ACTH), and potassium are three principal factors that adjusted aldosterone secretion (9,10).

Classical effects of aldosterone are to promote sodium retention and potassium loss by the kidney, although it exerts similar but lesser effects on the colon, sweat, and salivary glands (11). Aldosterone/mineralocorticoid receptor (MR) system plays an important role in cardiovascular and renal diseases, particularly in the presence of excessive salt intake. In individuals with metabolic syndrome, adipocyte-derived aldosterone-releasing factors cause inappropriate release of aldosterone in the adrenal glands during salt loading, resulting in the development of salt-induced hypertension, cardiac and renal damage (12). Aldosterone also plays a definitive role on systemic and vascular insulin resistance, as the vascular insulin resistance is considered an early cause to vascular damage. Accordingly, aldosterone impairs insulin receptor (IR) signaling by changing in the phosphatidylinositol 3-kinase (PI3K) / nitric oxide (NO) pathway and by inducing oxidative stress and crosstalk between the IR and the insulin-like growth factor-1 receptor (IGF-1R) leading to proliferation, oxidative stress and inflammation. Meanwhile, aldosterone exerts negative effects on structural and functional integrity of the pancreatic β-cell by encouraging inflammatory and oxidative stress conditions, which lead to decreased insulin release and actions, including actions in the vasculature (13).

Aldosterone is a new and axial factor that causes vascular calcification (VC) (14). Also, it has a detrimental effect in the vasculature (enhances
vascular oxidative stress), promote vessel inflammation and apoptosis (15). One of hemodynamic pathway factors is aldosterone hormone, aldosterone can promote vascular change and calcification in patients with diabetes through several mechanisms (16).

A wide range of biomarkers has been studied for identification of type 2 diabetes patients at microvascular and macrovascular risk. Fetuin-A is a novel biomarker that is used with metabolic complication to understand the causes that lead to microvascular or macrovascular changes that occur in diabetic nephropathy (17). Fetuin-A is a 60 kDa (kilo Dalton) glycoprotein produced exclusively by the liver and secreted into serum in relatively high concentrations in humans (18). Fetuin-A is known to inhibit ectopic calcium deposition and protect from vascular calcification (19). Epidemiological studies suggested that higher serum fetuin-A levels are associated with insulin resistance (IR), metabolic syndrome (MS) and Type2DM (20).

**Subjects and Methods**

The study was conducted on patients with type2 diabetes mellitus in AL Kindy Specialized Center for Endocrinology and Diabetes. For the period from November/2017 to February 2018. A total number of 60 diabetic patients (30 males and 30 females) were included in this study, 32 patients were positive for microalbuminuria and 28 were negative for microalbuminuria ,and their age ranged between (40) and (65) with a mean ±SD of (53.28±7.20 years). Patients were selected after excluding those on insulin therapy, hypertensive patients, or those with thyroid disorder or other endocrinopathies, or those with active liver diseases, pregnant females and smokers. Those patients were compared to 26 apparently healthy subjects (13 males&13 females). The study was approved by The Local Research Ethics Committee and all subjects were signed on a written informed consent to participate in this study.

Testing for microalbuminuria was performed by using (Combina 13) urine test strip (21) purchased by Human Diagnostic worldwide, Germany .While, fasting glucose, creatinine and urea were measured by COBAS C 311 ROCH analyzer (22-24). Glycoheamoglobin(HbA1c) was measured by spectrophotometer Apel PD-303(25). Serum electrolytes (Sodium, Potassium, and Chloride ) were estimated based on the potentiometric difference between the sample (electrodes) and reference standard, using Fuji Dri-chem NX 500 Electrolyte analyzer(26). Specific competitive binding ELISA kit for human aldosterone, purchased by Demiditic, Germany (27). Serum fetuin A levels were measured by utilizing quantitative sandwich ELISA kit from Cusabio, Shanghai /China (28).

**Glomerular Filtration Rate Determination :**

1. The Cockcroft-Gault Formula CCr=((140-age) x weight)/(72 SCr) x 0.85 if female , where CCr is expressed in milliliters per minute, age in years, weight in kilograms, and serum creatinine (SCr) in milligrams per deciliter (29).

2. Modification of Diet in Renal Disease Equation (The 4-variable MDRD Study equation): GFR = 175 x (Standardized SCr)-1.154 x (age)-0.203x (0.742 if female) x (1.210 if African American) GFR is expressed in mL/min/1.73 M2 Cr is serum creatinine expressed in mg/dL, and age is expressed in years (30).

Statistical analysis was performed using the SPSS statistical package for Social Sciences (version 20.0 for Windows, SPSS, Chicago, IL and USA). Data are presented as means ± SD. Significance was set at p < 0.05. Cases and controls were compared using either the t-test for independent samples. The Pearson coefficient test was used to test the relation between studied parameters.

**Results**

Subject’s characteristics are listed below in Table-1.
Table (1) Subject characteristics

| Parameters                  | Group                                | P value |
|-----------------------------|--------------------------------------|---------|
|                            | Patient (N=60)                       | Control (N=26) |       |
|                            | Mean       | SD  | Mean       | SD  |       |
| **Age (years)** *           | 53.28      | 7.20| 47.88      | 6.35| 0.001  |
| **Gender (M/F)**            | 30:30      |     | 13:13      |     | 0.999  |
| **Weight (Kg)** *           | 77.81      | 18.61| 70.77      | 7.11| 0.013  |
| **BMI (Kg/m\(^2\))** *     | 29.46      | 6.18| 26.32      | 2.14| 0.001  |
| **Duration of DM (years)**  | 7.29       | 5.20| .           | .   | -      |
| **FSG (mmol/L)** *          | 12.20      | 4.64| 5.12       | .63 | 0.005  |
| **HbA1C (%)** *             | 8.24       | 1.84| 4.62       | .88 | 0.005  |
| **Creatinine (µmol/L)**     | 71.57      | 37.56| 71.38      | 8.25| 0.972  |
| **Urea (mmol/L)**           | 4.21       | 1.13| 3.87       | .93 | 0.179  |
| **GFR MDRD (ml/min1.73m\(^2\))** | 105.26     | 42.35| 94.42      | 9.47| 0.064  |
| **GFR Crock ( ml/min)**     | 117.98     | 45.39| 106.35     | 10.45| 0.065  |
| **Albuminuria( mg)** *      | 34.00      | 46.07| .00        | .00 | 0.005  |
| **Sodium (mEq/L)**          | 119.5      | 15.0| 140.7      | 3.9 | 0.005  |
| **Potassium(mEq/L)**        | 3.9        | .5  | 4.1        | .1  | 0.199  |
| **chloride(mEq/L)**         | 82.5       | 11.0| 99.6       | 4.3 | 0.005  |
| **SBP (mmHg)** *            | 13.43      | 1.80| 12.15      | .54 | 0.005  |
| **DBP( mmHg )** *           | 8.47       | 1.19| 8.08       | .39 | 0.026  |
| **Aldosterone (Pg/ml)**     | 145.63     | 68.51| 116.03     | 134.14| 0.179 |
| **Fetuin-A**                | 628.76     | 829.14| 254.83     | 151.00| 0.001 |

* = significantly different from control, Body Mass Index (BMI), Fast Serum Glucose (FSG), GlycoHemoglobin (HbA1C), Glomerular Filtration Rate (GFR), Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP)

As shown in (Figure -1), the mean values of fasting serum glucose (FSG) and glyco hemoglobin (HbA\textsubscript{1c}) of group A (diabetic patients with positive +ve microalbuminuria) and group B (diabetic patients with negative –ve microalbuminuria) were significantly higher than group C (control).
Furthermore, mean values of GFR (Cockcroft-Gault Formula) for groups A and B were not significantly different from that of group C (the control), although these values were elevated as compared to that of group C as shown in (Figure -2).

![Figure (2) Mean of GFR (ml/min) (Cockcroft-Gault Formula) In: Group A (Diabetic Positive microalbuminuria). Group B (Diabetic Negative microalbuminuria). Group C (Control).]

Mean values of serum creatinine level for groups A and B were not significantly different from that of group C (the control)

![Figure (3) Mean values of serum creatinine level in: Group A =Diabetic positive microalbuminuria. Group B =Diabetic Negative microalbuminuria. Group C =Control.]

Data analysis of the estimated serum values of aldosterone among studied groups indicate a non significant difference between diabetics (with and without microalbuminuria) and the control subjects (figure-4).

![Figure (4) Mean values of serum aldosterone levels]
As illustrated in figure-5 serum fetuin-A levels were significantly elevated in group A (diabetic positive microalbuminuria) when compared to group B (diabetic negative microalbuminuria) as well as when compared to group C (Control).

![Figure (5) Mean values of Serum fetuin-A levels](image)

**Figure (5) Mean values of Serum fetuin-A levels**

*\( ^* \) significantly different from other groups
Group C differ from groups A and B

Whereas, in group B (diabetic negative microalbuminuria) Pearson’s correlation coefficient values of 0.388 and P value 0.041 indicating significant correlation between weight and aldosterone levels (Figure-7).

![Figure (6) Significant correlation between BMI and GFR (Crock-Gault) in group A](image)

**Figure (6) Significant correlation between BMI and GFR (Crock-Gault) in group A**

As shown in (figure-8) Pearson’s correlation coefficient values of 0.390 and P value 0.040 indicating significant correlation between serum chloride (Cl) and fetuin-A levels in diabetics without microalbuminuria.

![Figure (7) Significant correlation between weight and aldosterone in group B](image)

**Figure (7) Significant correlation between weight and aldosterone in group B.**

Whereas, Pearson’s correlation coefficient values of 0.431 and P value 0.022 indicating significant correlation between serum sodium and fetuin-A in non-albuminuric diabetics, as presented in (figure-9).

![Figure (8) Significant correlation between chloride and fetuin-A in group B.](image)

**Figure (8) Significant correlation between chloride and fetuin-A in group B.**
The level of glycemic control seems to be the strongest factor influencing transition from normoalbuminuria to microalbuminuria\(^{(31)}\). Glycemic control plays as vital role in diabetic microvascular complications. It was shown that for each 1% reduction in updated mean of HbA1c there is a 37% reduction in microvascular complication risks\(^{(32)}\).

The FSG in diabetic patients mean value was (12.20±4.64 m mol/L) and HbA1c mean was (8.24±1.84 %) which is significantly higher than the control group (mean FSG 5.12±0.63 m mol/L, HbA1c mean 4.62±0.88%), as summarized in (figure-1). There was no positive correlation between FSG, HbA1c and microalbuminuria, in contrast to a study by Chen et al\(^{(31)}\).

Considering renal function assessment; the mean values of serum creatinine and estimated GFR were within normal range for both groups (Group A diabetics with positive microalbuminuria and Group B diabetics with negative microalbuminuria as shown in (figure-2) and (figure-3). Estimated GFR and serum creatinine depend on the renal hemodynamics, systemic blood pressure, urinary findings, and susceptibility to therapeutic intervention. On the basis of these findings, it is concluded that microalbuminuria may not be associated with abnormal creatinine or creatinine clearance.\(^{(33)}\)

Among the important parameters that had been shown to directly affect renal haemodynamics and alter the afferent/efferent balance, is BMI which could result in glomerular hypertension, hyperfiltration and ultimately, renal injury\(^{(34)}\). The present study shows a positive correlation between (BMI, weight) and estimated GFR (Crock-Gault) in diabetic patient with positive microalbuminuria as in (figure-6). Studies had explained the assessment of GFR in relation to body dimensions, however, it is important to be aware that renal function equations are subjected to BMI-associated bias, for example: Kwakernaak et al compared between Cockcroft–Gault and Modification of Diet in Renal Disease (MDRD) in healthy subject, and found that the effect of BMI on overestimation of GFR was the largest for Cockcroft–Gault and less for MDRD\(^{(35)}\). The renal haemodynamic profile in overweight and obesity, and in subjects with a central body fat distribution, may be affected by other factors which are sodium intake and volume homeostasis, as well as long-term susceptibility to renal damage.\(^{(36, 37)}\) Interestingly, in young normotensive subjects, overweight is associated with a rise in filtration fraction (FF) in response to high salt intake, whereas in lean subjects GFR increases without a rise in FF. In overweight subjects, moreover, a high salt intake is associated with a larger increase in the extra cellular volume (ECV) than in lean subjects, supporting the impact of subtle changes in renal haemodynamics on volume homeostasis\(^{(38)}\), as being presented in this study with a positive correlation between body weight and serum aldosterone (figure-7) in group B diabetic patients. The long-term consequences of this unfavorable renal haemodynamic profile, elicited by the combination of overweight and excess sodium intake may well contribute to the development of salt-sensitive hypertension and renal damage later in life\(^{(39)}\).

Diabetic patients are more prone to develop electrolyte disturbances because of disease state itself and associated disruption of blood glucose homeostasis. The Use of antidiabetic drugs also leads to the development of electrolyte disturbances\(^{(40)}\). In the present study, the mean values of serum Na+ level in both groups of diabetic patients were significantly reduced compared to control group (Table-1). Similar findings were observed by Alaka Das\(^{(41)}\).

There were individual variations in sodium level in both groups of diabetic patients some of them were within normal range, but others were under normal range. Hyponatremia is the most common electrolyte abnormality in clinical practice and is associated with increased morbidity and mortality and even small decreases of serum sodium are associated with increased probability for adverse outcomes\(^{(42)}\). Drugs represent a common cause of hyponatremia in individuals with diabetes\(^{(42)}\). Such as the first generation sulphonylureas (tolbutamide and chlorpropamide)\(^{(43, 44)}\). Other drugs of common utilizations include NSAIDs, angiotensin converting
enzyme inhibitors, rosiglitazone or even amlodipine. Patients with central nervous system disorders, pulmonary disorders including lung infections, and malignancies may exhibit hyponatremia due to the syndrome of inappropriate antiuretics. Patients with diabetic nephropathy and chronic renal failure are very prone to the development of hyponatremia due to decreased water excretion [42]. Furthermore, potassium levels in both groups of diabetic patients were near to normal range, with no significant change in serum K+ level had been observed between the diabetic group and control group. Similar findings were reported by Alaka Das (41).

Although there were elevated serum aldosterone levels in microalbuminuric diabetics but the wide variation of these values when analyzed statistically were not of enough significance when compared with mean value of diabetic negative microalbuminuria and control group (Figure- 4) which are similar to the result obtained by Hollenberg et al (45). Meanwhile, a positive correlation between weight and serum aldosterone level was observed in group B patients (figure-7), similarly Tuck et al, demonstrated that weight loss is accompanied by reductions in PRA (plasma renin activity) and aldosterone, irrespective of sodium intake, and this affects the decline in BP in obese patients [46]. Interestingly, high levels of PRA, ACE, aldosterone, and insulin with sodium retention and potassium loss were found in patients with visceral obesity, but all of these tended to disappear upon weight reduction and were not found in patients with peripheral obesity [47]. Another study demonstrated that the PAC (plasma aldosterone concentration) is positively correlated with the amount of visceral adipose tissue and is inversely correlated with insulin sensitivity, independent of the PRA level. This suggested that a fat derived substance contributes to aldosterone excess in patients with visceral obesity [48].

Fetuin-A had been reported to have a role in causing vascular calcification in diabetic patient, fetuin-A gives a picture if the patient has calcium deposition in vascular (calcification occurs or not), it is a multifunctional glycoprotein predominantly secreted by the liver and mainly involved in promoting insulin resistance [49]. Accumulating experimental and epidemiological studies reported that it was associated with a spectrum of cardiometabolic disorders, such as metabolic syndrome [50], nonalcoholic fatty liver disease [51], T2DM [52], and cardiovascular diseases (CVD) [53]. A study by LV X et al showed a positive association between serum fetuin-A levels and albuminuria in patients with metabolic syndrome or T2DM [54], however, no such correlation had been detected in this study.

Furthermore, the mean value of serum fetuin-A in diabetics with positive microalbuminuria was higher than that in diabetics with negative microalbuminuria and control group (Figure-5) and this indicated to uncontrolled DM.

In this study, we evaluated the associations of some parameters related to microvascular diseases in patients with T2DM and early diabetic nephropathy as the degree of albumin excretion, renal function (GFR and serum creatinine). All of these parameters showed no significant correlation with fetuin A, nor to correlate with some clinical and metabolic parameters as BMI, blood pressure which are similar to the study by Ayman Ramadan et al (55).

However, it had been found that fetuin-A levels seem to be associated with prevalent macrovascular disease (as coronary artery disease, stroke and peripheral artery disease) in T2DM, and fetuin-A serum levels are not associated with microvascular complications (24 h urinary albumin excretion) in patients with early diabetic nephropathy [56] which almost in agreement with our study in some extent in that fetuin-A levels do not correlate with metabolic parameters in T2DM patients with prevalent late complications.

On the other hand, serum fetuin-A showed a positive correlation with serum chloride in group B as shown in (figure-8) and this is obvious that chloride is most commonly associated with proportionate changes in sodium concentration so therefore, the concentration of Cl usually parallels to that of sodium and may correlate with fetuin A in same mechanism that control serum level of sodium through (RAAS activation, higher insulin concentration) causing sodium retention with a parallel increase in chloride level [57]. Similarly, a positive correlation between serum sodium level and fetuin-A is present as shown in (figure-9). In diabetic patient, there are 2 mechanisms that cause sodium retention, first one is the activation of (RAAS), whereas the second, T2DM, have a high circulating insulin level but lack its functional role in regulating glucose level, and insulin thought to have a role in increasing sodium level by its antidiuretic effect. High concentration of fetuin A in patients with type 2 diabetes is associated with increasing insulin level; these two mechanism may counteract the osmotic diuresis that occur due to hyperglycemia [58].

According to their result of this study, it is concluded that in diabetic patient with microalbuminuria it may not necessary to have high serum level of aldosterone besides that aldosterone hormone is not the only factor that cause calcification. Calcification may occur due to diabetes itself. Microalbuminuria in diabetics may not associate with the decline in renal function or a change in estimated
References
1. Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: Challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032–45.
2. Adler AI, Stevens RJ, Manley SE, Bilous RW, et al. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63(1):225–32.
3. Koroshi A. Microalbuminuria, is it so important? Hippokratia. 2007;11(3):105–7.
4. Gross JL, De Azevedo MJ, Silveiro SP, Canani H, et al. Diabetic Nephropathy: Diagnosis, Prevention, and Treatment. Diabetes Care. 2005;28:176–88.
5. Roett MA, Liegl S, Jabbarpour Y. Diabetic nephropathy-The family physician’s role. Am Fam Physician. 2012;85(9):883–9.
6. Satirapoj B, Adler SG. Comprehensive approach to diabetic nephropathy. Kidney Res Clin Pract. 2014;33(3):121–31.
7. Ziyadeh FN, Wolf G. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetess. 2008;4(1):39–45.
8. Cao Z, Cooper ME. Pathogenesis of diabetic nephropathy. J Diabetes Investig. 2011;2(4):243–7.
9. Nakhoul R, Nakhoul F, Nakhoul N. Diabetic Nephropathy from RAAS to Autohypophagy: The Era for New Players. J Clin Exp Nephrol. 2017;2(3):1–8.
10. Epstein M. Aldosterone as a determinant of cardiovascular and renal dysfunction. J R Soc Med. 2001;94(8):378–83.
11. McFarlane SI, Sowers JR. Cardiovascular endocrinology I: Aldosterone function in diabetes mellitus: Effects on cardiovascular and renal disease. J Clin Endocrinol Metab. 2003;88(2):516–23.
12. Shibata S, Fujita T. The kidneys and aldosterone/mineralocorticoid receptor system in salt-sensitive hypertension. Curr Hypertens Rep. 2011;13(2):109–15.
13. Bruder-Nascimento T, da Silva MA, Tostes RC. The involvement of aldosterone on vascular insulin resistance: implications in obesity and type 2 diabetes. Diabetol Metab Syndr. 2014;6(1):90.
14. Catena C, Colussi GL, Nait F, Martinis F, et al. Aldosterone and the heart: Still an unresolved issue? Front Endocrinol (Lausanne). 2014;5(OCT):1–5.
15. Moss ME, Jaffe IZ. Mineralocorticoid Receptors in the Pathophysiology of Vascular Inflammation and Atherosclerosis. Front Endocrinol (Lausanne). 2015;6(September):1–7.
16. Gao J, Zhang K, Chen J, Wang J, et al. Roles of aldosterone in vascular calcification: an update. Eur J Pharmacol. 2016;5:30.
17. Kim HC, Greenland P, Rossouw JE, Manson JAE, et al. Multimarker Prediction of Coronary Heart Disease Risk. The Women’s Health Initiative. J Am Coll Cardiol. 2010;55(19):2080–91.
18. Jung C-H, Kim B-Y, Kim C-H, Kang S-K, et al. Associations of serum fetuin-A levels with insulin resistance and vascular complications in patients with type 2 diabetes. Diabetes Vasc Dis Res. 2013;10(5):459–67.
19. Cai MMX, Smith ER, Holt SG. The role of fetuin-A in mineral trafficking and deposition. Bonekey Rep. 2015;4(MAY):1–10.
20. Song A, Xu M, Bi Y, Xu Y, et al. Serum fetuin-A associates with type 2 diabetes and insulin resistance in Chinese adults. PLoS One. 2011;6(4).
21. Penders J, Fiers T, Delanghe JR. Quantitative evaluation of urinary urea test strips. Clin Chem. 2002;48(12):2236–41.
22. Burrin JM, Price CP. Measurement of blood glucose. Ann Clin Biochem. 1985;22 ( Pt 4):327–42.
23. Bowers LD, Wong ET. Kinetic serum creatinine assays. II. A critical evaluation and review. Clin Chem. 1980;26(5):555–61.
24. Sampson EJ, Baird MA, Burstis CA, Smith EM, et al. A coupled-enzyme equilibrium method for measuring urea in serum: Optimization and evaluation of the AACC study group on urea candidate reference method. Clin Chem. 1980;26(7):816–26.
25. Memon MY, Mughal MA, Memon SH, Rahu AA. iMedPub Journals Correlation of Microalbuminuria with Glycated Hemoglobin.
Blood Pressure and Duration of Diabetes Abstract. 2017;1–7.

26. Burnett RW, Covington AK, Fogh-Andersen N, Küllpmann WR, et al. Use of ion-selective electrodes for blood-electrolyte analysis. Recommendations for nomenclature, definitions and conventions. Clin Chem Lab Med. 2000;38(4):363–70.

27. Borrebaeck C. Recent Developments in Heterogenous Enzyme Immunoassay. solid phase J. 1979;4(1):57–8.

28. Wisdom GB. Enzyme-Immunnoassay. Clin Chem Clin Chem. 1976;228(8):1243–55.

29. Cockcroft DW, Gault H. Prediction of Creatinine Clearance from Serum Creatinine. Nephron. 1976;16(1):31–41.

30. Levey AS, Coresh J, Greene T, Marsh J, et al. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007;53(4):766–72.

31. Chen W-Z, Hung C-C, Wen Y-W, Ning H-C, et al. Effect of glycemic control on microalbuminuria development among type 2 diabetes with high-normal albuminuria. Ren Fail. 2014;36(2):171–5.

32. Stratton IM. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Bmj. 2000;321(7258):405–12.

33. Kondaveeti SB, D K, Mishra S, Kumar R A, Shaker IA. Evaluation of glycated albumin and microalbuminuria as early risk markers of nephropathy in type 2 diabetes mellitus. J Clin Diagn Res. 2013;7(7):1280–3.

34. Bosma RJ, Homan Van Der Heide JJ, Oosterop EJ, De Jong PE, et al. Body mass index is associated with altered renal hemodynamics in non-obese healthy subjects. Kidney Int. 2004;65(1):259–65.

35. Kwakernaak AJ, Toering TJ, Navi G. Body mass index and body fat distribution as renal risk factors: A focus on the role of renal haemodynamics. Nephrol Dial Transplant. 2013;28(SUPPL.4):42–9.

36. Bigazzi R, Bianchi S, Baldari D, Gherri G, et al. Microalbuminuria in Salt-Sensitive Patients. Hypertension. 1994;23(2 February):195–200.

37. Campese VM, Parisie M, Karubian F, Bigazzi R. Abnormal renal hemodynamics in black salt-sensitive patients with hypertension. Hypertension. 1991;18(6):805–12.

38. Krikken JA, Lely AT, Bakker SJL, Navis G. The effect of a shift in sodium intake on renal hemodynamics is determined by body mass index in healthy young men. Kidney Int. 2007;71(3):260–5.

39. Bosma RJ, Kwakernaak AJ, Homan Van Der Heide JJ, De Jong PE, et al. Body mass index and glomerular hyperfiltration in renal transplant recipients: Cross-sectional analysis and long-term impact. Am J Transplant. 2007;7(3):645–52.

40. Palmer BF, Clegg DJ. Electrolyte and Acid–Base Disturbances in Patients with Diabetes Mellitus. N Engl J Med. 2015;373(6):548–59.

41. Alaka Das SB. Evaluation of Serum Electrolyte Levels in Type 2 Diabetes Mellitus Dr Saurabh Borkotoki. Indian J Appl Res. 2016;6(August):91–3.

42. Vasilios GL. Hyponatremia in Diabetes Mellitus: Clues to Diagnosis and Treatment. J Diabetes Metab. 2015;06(06).

43. Liams M. Diabetes mellitus and electrolyte disorders. World J Clin Cases. 2014;2(10):488.

44. Van Blijderveen JC, Strauss SM, Rodenburg EM, Zietse R, Stricker BH, et al. Risk of hyponatremia with diuretics: Chlorthalidone versus hydrochlorothiazide. Am J Med. 2014;127(8):763–71.

45. Hollenberg NK, Stevanovic R, Agarwal A, Lansang MC, et al. Plasma aldosterone concentration in the patient with diabetes mellitus: Rapid communication. Kidney Int. 2004;65(4):1435–9.

46. Kawarazaki W, Fujita T. The role of aldosterone in obesity-related hypertension. Am J Hypertens. 2016;29(4):415–23.

47. Ruano M, Silvestre V, Domínguez Y, Castro R, et al. Morbid obesity, hypertensive disease and the renin-angiotensin-aldosterone axis. Obes Surg. 2005;15(5):670–6.

48. Goodfriend TL, Kelley DE, Goodpaster BH, Winters SJ. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes Res. 1999;7(4):355–62.

49. Denecke B, Aber SGR, Afer CSCH, Heiss A, et al. Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-A. Biochem J. 2003;145:135–45.

50. Ix JH, Shlipak MG, Brandenburg VM, Ali S, et al. Association Between Human Fetuin A and the Data From the Heart and Soul Study. Circulation. 2006;113(3):1760–8.

51. Haukeland JW, Dahl TB, Yndestad A, Gladhaug IP, et al. Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies. Eur J Endocrinol. 2012;166:503–10.

52. Sun Q, Cornelis MC, Manson JE, Hu FB. Plasma Levels of Fetuin-A and Hepatic Enzymes and Risk of Type 2 Diabetes in Women in the U.S. Diabetess. 2013;62(JANUARY):49–55.

53. Weikert C, Stefan N, Schulze MB, Pischon T, et al. Plasma Fetuin-A Levels and the Risk of
Myocardial Infarction and Ischemic Stroke. Circulation. 2008;118:2555–2562.

54. Lv X, Sun W, Huang X, Chen Y, et al. Association of Serum Fetuin-A Levels With the Risk of Albuminuria in Middle-Aged and Elderly Chinese. J Clin Endocrinol Metab. 2018;101(March 2016):1235–42.

55. Ramadan A, Shoukry A, Ismail MI, Borai M, Departments CP. Serum Fetuin-A Levels in Type 2 Diabetes Patients with Early Diabetic Nephropathy: It’s Relation to Diabetes Control. 2011;7(5):759–65.

56. Roos M, Oikonomou D, Eynatten M Von, Luppa PB, et al. Associations of Fetuin-A levels with vascular disease in type 2 diabetes patients with early diabetic nephropathy. Cardiovasc Diabetol. 2010;48(9):1–7.

57. Hu Y, Dietrich D, Xu W, Patel A, et al. Hypochloraeemia is strongly and independently associated with mortality in patients with chronic heart failure. Arch Oral Biol. 2015;59(8):855–70.

58. Brands MW, Manhiani MM. Sodium-retaining effect of insulin in diabetes. AJP Regul Integr Comp Physiol. 2012;303(11):1101–9.